Biogen
↗Cambridge, Massachusetts, USA
Biogen is a leading biotechnology company pioneering innovative science to discover, develop, and deliver medicines for patients with serious illnesses. Founded in 1978, the company specializes in neurological and neurodegenerative diseases, including multiple sclerosis (MS), Alzheimer's disease, spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS), and immunological conditions. With operations across the Americas, Europe, Asia, and other territories, Biogen is recognized as a big pharma player with significant research and development capabilities. The company has undergone strategic transformation in recent years, making targeted acquisitions to expand its pipeline and manufacturing capabilities while managing patent cliffs on legacy products.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:-
Industry:Pharmaceuticals
Sub-Industry:Neurology, Neurodegeneration, Immunology, Rare Disease
SIZE & FINANCIALS
Employees:5001-10000
Revenue:$10B+
Founded:1978
Ownership:public
Status:operating
FUNDING
Stage:N/A - Public Company
STOCK
Exchange:NASDAQ
Ticker:BIIB
Market Cap:$21.9B-$26.1B
PIPELINE
Stage:Phase 1-Phase 3; Commercial
Lead Drug Stage:LEQEMBI (lecanemab) - Phase 3 (approved for early Alzheimer's)
Modalities:Small molecule, Monoclonal antibodies, Antisense oligonucleotides (ASO), Gene therapy, RNA therapy, Biosimilars
Active Trials:50
Trial Phases:Phase 1: 12 | Phase 2: 18 | Phase 3: 15 | Phase 4: 5
FDA Approvals:20
EMA Approvals:15
CORPORATE STRUCTURE
Subsidiaries:Human Immunology Biosciences (HI-Bio) - acquired May 2024, Reata Pharmaceuticals - acquired July 2023, Alcyone Therapeutics - acquired November 2025
Key Partnerships:Eisai - Co-commercialization of LEQEMBI and Aduhelm for Alzheimer's, Sage Therapeutics - Co-development and profit-sharing for Zurzuvae (postpartum depression), City Therapeutics - Strategic collaboration on RNAi therapies ($46M upfront, up to $1B in milestones), Ionis Pharmaceuticals - ASO development partnerships
COMPETITION
Position:Leader
Competitors:Eli Lilly (Kisunla/donanemab for Alzheimer's), Eisai (LEQEMBI co-partner, independent pipeline), AC Immune (Alzheimer's and neurodegenerative disease), Prothena (neurodegeneration focus), Vertex Pharmaceuticals (cell and gene therapy), Moderna (mRNA therapeutics), Roche/Genentech (neurology and immunology), Regeneron (immunology) +2 more
LEADERSHIP
Key Executives:
Christopher A. Viehbacher - President and Chief Executive Officer
Michael McDonnell - Executive Vice President and Chief Financial Officer
Susan H. Alexander - Executive Vice President, Chief Legal Officer and Corporate Secretary
Ginger Gregory - Chief Human Resources Officer
Alisha A. Alaimo - President, Head of North America
Wolfram Schmidt - President, Head of Europe
Adam Keeney - Executive Vice President and Head of Corporate Development
Scientific Founders:Wally Gilbert, Phillip Sharp, Dimitri Karneros
Board Members:Caroline Dorsa (Chair of the Board), Christopher A. Viehbacher (President and CEO (Board Member)), Sir Menelas Pangalos (Independent Director), Lloyd B. Minor (Independent Director), Jesus B. Mantas (Independent Director, Chair of Compensation and Management Development Committee), Monish Patolawala (Independent Director)
LINKS
Website:biogen.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Biogen. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.